Press release
Biosimilars Market Anticipated to Exceed USD 125.9 Billion by 2035
Biosimilars Market Anticipated to Exceed USD 125.9 Billion by 2035
MarketGenics, a global market research and consulting company, has released its latest study on the biosimilars market, spotlighting the role of patent expiries, affordability needs, and supportive regulatory frameworks in fueling rapid adoption worldwide.
Get the complete market breakdown - statistics, insights, and future outlook: https://marketgenics.co/reports/biosimilars-market-04169
Market Outlook
The global biosimilars market is expected to expand from USD 31.6 Billion in 2024 to USD 125.9 Billion by 2035, growing at a CAGR of 13.4%.
Key growth factors include:
Patent expirations of blockbuster biologics like Humira, Herceptin, and Avastin.
Expanding demand for affordable biologic therapies in oncology, autoimmune, and metabolic diseases.
Smart delivery systems (e.g., connected injection pens, app-based compliance tools) that improve adherence and confidence.
Government initiatives to increase awareness, integrate biosimilars into medical guidelines, and encourage substitution.
Industry Developments
Launch of New Biosimilars (2024) - Expanded portfolios introduced across the U.S., Europe, and Asia for hospital and home-care use.
Digital Integration - Injection pens linked to smartphone apps enable real-time adherence tracking and reporting.
Policy Momentum - Regulators including FDA, EMA, and Health Canada strengthening approval pathways and patient education efforts.
To know more about the Biosimilars Market - Download our Sample Report: https://marketgenics.co/download-report-sample/biosimilars-market-04169
Market Dynamics
Drivers - Growing chronic disease prevalence, affordability demand, and government-backed adoption programs.
Restraints - Long regulatory pathways, high R&D costs, patent litigation by originator companies, and lingering provider/patient hesitancy.
Opportunities - Expansion of companion diagnostics, biosimilar education programs, and increasing use of digital health solutions for treatment monitoring.
Impact of Tariff & Trade Regulations
The biosimilars industry is influenced by global tariff and trade policies:
High tariffs on biosimilar imports raise deployment costs, limiting affordability and discouraging cross-border trade.
Export restrictions force manufacturers to establish localized production hubs, driving up R&D and manufacturing costs but stimulating domestic industries.
Low-tariff regions enable faster adoption, encouraging partnerships and flexible supply chains.
Manufacturers are adapting by building regional alliances, flexible manufacturing ecosystems, and supply chain redundancies to mitigate tariff risks.
Expansion of the Biosimilars Market
"Rapid Expansion Fueled by Patent Expiries, Affordability, and Regulatory Advancements"
The biosimilars sector is positioned for rapid growth as:
Expired biologic patents unlock vast opportunities in oncology, immunology, and endocrinology.
Value-based healthcare pressures drive demand for cost-effective biologic substitutes.
Regulatory progress (FDA, EMA, Health Canada) supports quicker approvals and stronger education programs.
Strategic collaborations and R&D in advanced manufacturing reinforce biosimilar pipelines.
As trust grows among patients and healthcare professionals, biosimilars are poised to redefine equitable and sustainable access to high-cost treatments.
Get the Detailed Industry Analysis (including the Table of Contents, List of Figures, and List of Tables) - from the Biosimilars Market Research Report: https://marketgenics.co/press-releases/biosimilars-market-04169
Regional Analysis
North America - Growing acceptance of biosimilars driven by supportive FDA guidance, payer incentives, and physician confidence.
Europe - Mature market with specialized EMA pathways and strong hospital adoption.
Asia Pacific - Rapidly expanding due to large patient populations, government-driven affordability initiatives, and emerging hubs in India, China, and South Korea.
Middle East & Africa - Gradual adoption supported by public health initiatives focused on reducing treatment costs.
South America - Biosimilar uptake improving via regional cost-control strategies and healthcare access reforms.
Key Players in the Global Biosimilars Market
Accord Healthcare Ltd., Alvotech, Amgen Inc., Apotex Inc., Biocon Biologics Ltd., Boehringer Ingelheim, Celltrion Inc., Coherus BioSciences, Dr. Reddy's Laboratories, Eli Lilly and Company, Fresenius Kabi, Intas Pharmaceuticals Ltd., Kashiv BioSciences LLC, Merck KGaA, Mylan N.V. (Viatris), Nichi-Iko Pharmaceutical Co., Ltd., Novartis AG (Sandoz), Pfizer Inc., Reliance Life Sciences, Roche Holding AG, Samsung Bioepis, Sanofi S.A., Shanghai Henlius Biotech Inc., STADA Arzneimittel AG, Teva Pharmaceutical Industries Ltd., Xbrane Biopharma AB, and other key players.
About Us
MarketGenics is a global market research and management consulting company empowering decision makers across healthcare, technology, and policy domains. Our mission is to deliver granular market intelligence combined with strategic foresight to accelerate sustainable growth.
We support clients across strategy development, product innovation, healthcare infrastructure, and digital transformation.
Contact:
Mr. Debashish Roy
MarketGenics India Pvt. Ltd.
800 N King Street, Suite 304 #4208, Wilmington, DE 19801, United States
USA: +1 (302) 303-2617
Email: sales@marketgenics.co
Website: https://marketgenics.co
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biosimilars Market Anticipated to Exceed USD 125.9 Billion by 2035 here
News-ID: 4185997 • Views: …
More Releases from MarketGenics India Pvt. Ltd.
APAC Deepfake Detection Market Accelerates as Governments Tighten Digital Trust …
A Market Transforming How the World Verifies Reality
The global deepfake detection technology market, valued at USD 0.6 billion in 2025, is positioned to accelerate at a powerful 37.2% CAGR, reaching USD 15.1 billion by 2035.
This growth is driven by one undeniable truth:
Synthetic media is reshaping the threat landscape faster than humans can recognize it.
Deepfake detection technologies now determine:
How newsrooms verify breaking content
How financial institutions prevent identity-spoofing
How governments protect election integrity
How…
Travel & Expense Management Software Market Signals a Digital Pivot | AI, Cloud …
The Travel and Expense Management (TEM) Market Crossroads | A Sector Accelerating, Repricing Efficiency, and Redrawing the Corporate Spend Map
(Is TEM a Back-Office Tool-or the Operating System of the Next Enterprise Economy?)
For years, the travel and expense management software market lived in the administrative shadows-handed off to finance teams, constrained by spreadsheets, and dismissed as a routine cost-control tool. But the numbers now tell a radically different story.
In 2025, the…
Oilfield Equipment Market hits USD 116.2B in 2025 and grows to USD 156.5B by 203 …
Oilfield Equipment Market | The $156.5B Hardware Backbone of the Global Energy System
Every headline loves clean energy. Yet the global energy mix still demands a brutal truth: oil and gas remain the world's primary supply of heat, mobility, and petrochemicals - and the machines that drill, lift, complete, and produce hydrocarbons continue to define industrial capability.
That's why the Oilfield Equipment Market remains a strategic industry - not a relic.
In 2025,…
Machine Tools Market 2025-2035 | USD 109.9B Growth, CNC & Automation Trends
Machine Tools Market | The $109.9B Intelligence Engine of Global Manufacturing
Factories don't work without machine tools. They shape, cut, drill, grind, and define the physical world around us. Yet most end-products - cars, aircraft parts, electronics housings, surgical devices - never reveal the precision machinery behind them.
The Machine Tools Market is the invisible infrastructure that turns digital models into physical reality.
In 2025, the global Machine Tools Market stands at USD…
More Releases for Biosimilar
Interchangeable Biosimilar Humira Market Share Driven by Biologic Therapy Adopti …
Interchangeable Biosimilar Humira Market
The global market for Interchangeable Biosimilar Humira was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period
View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-33I15005/Global_Interchangeable_Biosimilar_Humira_Market_Research_Report_2023
The Interchangeable Biosimilar Humira Market is experiencing significant market growth as healthcare providers and patients increasingly adopt biosimilar therapies for autoimmune and inflammatory conditions. Market trends indicate rising…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Get…
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02…
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
